Drug Delivery Deals

dear sir,
this helps them to improve their r&d and also to improve the standars of drugs isn't it?

Dear sir,
A good blog....what are the basic criteria or requirement seeked by a company while making such deals...
Regards,
Faria Zarrin
Team: BLOGBUSTERS

From the time Daiichi Sankyo acquired Ranbaxy, even low-key companies have trodden the acquisitions path. Abbott, for one, has struck a deal to lap up Wockhardt's nutritional brands.

If one report claims an equity deal between GlaxoSmithKline and Dr Reddy's close on the heels of a manufacturing and marketing arrangement for the emerging markets between them, barely three days later, another goes to town screaming Sanofi-Aventis has resumed long-deadlocked talks with Piramal Healthcare with the objective of acquiring a sizeable stake.

In fact, every company promoter seems to be salivating at the likelihood of getting the value the Ranbaxy promoters received from the Japanese major.The general feeling in the industry is that smaller or medium-sized companies would be the first to capitulate.

Even internationally reputed publications like the Wall Street Journal reported a few months ago of an interest in Piramal Healthcare by GSK and Sanofi-Aventis and hence the local M&A scene seems set for an unprecedented eruption after a long spell of slumber and passiveness.

Adding more fuel to the fire was the recent acquisition of vaccines and biologicals company Shantha Biotech by Sanofi-Aventis for a valuation that exceeded an irresistible $750 million. Pfizer had added one more dimension by entering into a supply alliance with Claris and Aurobindo Pharma.